rc48-adc
Angioimmunoblastic T-Cell Lymphoma Recurrent
BeiGeneantibody_drug_conjugatePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Angioimmunoblastic T-Cell Lymphoma Recurrent cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Mitoxantrone The Affiliated Hospital of Xuzhou Medical University | Phase 2 | B |
Tislelizumab The Affiliated Hospital of Xuzhou Medical University | Phase 2 | B |
Pyrotinib BeiGene | Phase 2 | B |
Same molecule, other indications
rc48-adc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →